Reducing glutamine levels in the body is not a casual health goal but a serious medical and research objective, most relevant to cancer treatment and severe liver disease. Glutamine is the most abundant amino acid in the bloodstream, and the body works hard to keep it available because nearly every tissue depends on it. Strategies for lowering it range from experimental drugs that block how cells use glutamine to dietary shifts and even intense physical activity, but each comes with trade-offs because glutamine is also essential for gut health, immune function, and brain chemistry.
Why Lowering Glutamine Matters in Medicine
The main reason researchers want to reduce glutamine availability is cancer. Many tumors become heavily dependent on glutamine to fuel their growth. The oncogene Myc, one of the most commonly activated drivers of cancer, reprograms cells so that their mitochondria rely on glutamine breakdown to keep their central energy cycle running. This creates what researchers call “glutamine addiction,” where cancer cells literally cannot survive without a steady supply of the amino acid.1PubMed Central. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction Starving those cells of glutamine, in theory, should slow or kill the tumor while leaving healthier cells relatively unharmed.
The other major clinical scenario involves the brain. In advanced liver disease, the liver cannot clear ammonia from the blood effectively. The brain converts that excess ammonia into glutamine through an enzyme called glutamine synthetase, but the buildup of glutamine inside brain cells causes them to swell. This swelling contributes to hepatic encephalopathy, a dangerous condition involving confusion, seizures, and sometimes death. In animal studies, blocking glutamine synthetase activity reduced brain swelling and lowered death rates in ammonia-intoxicated rats.2Annals of Hepatology. Hepatic encephalopathy, ammonia, glutamate, glutamine and oxidative stress – Section: Glutamine and its relation with brain edema In this context, the target is not whole-body glutamine levels but specifically glutamine accumulation in the brain.
Where Glutamine Comes From and Why It Is Hard to Deplete
Your body does not rely on diet alone for glutamine. Skeletal muscle, the liver, and the gut are the major organs that produce and release glutamine into the bloodstream.3PubMed Central. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation Skeletal muscle is the largest reservoir. Even if you ate no glutamine at all, your muscles would continue synthesizing and exporting it to meet the needs of your immune cells, kidneys, and gut lining. This endogenous production is one reason why simply cutting glutamine from your diet has only a limited effect on circulating levels.
Glutamine is also found in a wide range of foods. Meat, fish, eggs, dairy, beans, and even some vegetables all contain it. Because it appears in virtually every protein-containing food, achieving a truly low-glutamine diet would require extreme restriction that could lead to malnutrition. Interestingly, one animal study found that rats fed extra dietary glutamine actually saw their endogenous glutamine production drop, with turnover falling to about two-thirds of normal levels.4PubMed. Dietary glutamine suppresses endogenous glutamine turnover in the rat The body seems to have a thermostat: supply more from outside, and it dials back internal production. This self-regulation makes it genuinely difficult to shift overall glutamine levels through dietary changes alone.
Drugs That Block Glutamine Use in Cancer
Because simply lowering blood glutamine is so difficult, most pharmacological strategies target how cancer cells take up or break down glutamine rather than trying to drain it from the body entirely. There are three main classes of drugs in development.
Glutaminase Inhibitors
The first step after a cancer cell absorbs glutamine is breaking it down into glutamate, a reaction carried out by the enzyme glutaminase. An enzyme called GLS2 acts as a key regulator in this conversion and also influences the cell’s antioxidant defenses and energy production.5PubMed Central. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species Telaglenastat (also known as CB-839) is the most advanced drug in this category. It is an oral inhibitor of glutaminase that has been tested in phase I and II cancer trials and is generally well tolerated by patients.6PubMed Central. Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models It has also been tested in later-stage trials combined with other cancer drugs and immunotherapies.7PubMed Central. The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Anti-Melanoma Activity of T Cell Mediated Immunotherapies
The idea behind glutaminase inhibitors is surgical: block the enzyme that cancer cells need to process glutamine, and the rest of the body’s glutamine-dependent functions remain mostly intact. In practice, results have been mixed. Many tumors find workarounds, a problem explored later in this article. But the safety profile of telaglenastat has been encouraging enough to keep clinical trials going.
Broad Glutamine Antagonists
An older and more aggressive approach uses a compound called DON (6-diazo-5-oxo-l-norleucine), which mimics glutamine and jams multiple enzymes that use it. DON showed promising anticancer effects in early clinical trials decades ago but was shelved because it caused severe damage to the gastrointestinal tract.8PubMed Central. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug Researchers have since designed prodrug versions of DON, particularly one called DRP-104, that are engineered to activate preferentially inside tumors while being converted to an inert compound in gut tissues. Other teams have developed DON prodrugs with improved stability using different chemical approaches, all aimed at getting the drug to tumors while sparing the GI tract.9Journal of Medicinal Chemistry. Discovery of tert-Butyl Ester Based 6-Diazo-5-oxo-l-norleucine Prodrugs for Enhanced Metabolic Stability and Tumor Delivery
DON-based drugs are notable because they do not just block one enzyme. They interfere with glutamine at multiple metabolic steps simultaneously, which makes it harder for cancer cells to route around the blockade. The trade-off is a wider risk of side effects, though the newer prodrug designs are specifically trying to limit that collateral damage.
Ammonia Scavengers for Liver Disease
For patients with urea cycle disorders or liver failure, the goal is slightly different: rather than blocking glutamine metabolism in cancer cells, clinicians want to reduce excess ammonia that would otherwise be converted into glutamine in the brain. Drugs like glycerol phenylbutyrate (GPB) and sodium phenylbutyrate work by providing an alternative route for nitrogen disposal through the kidneys. In a phase 2 trial comparing GPB with sodium phenylbutyrate, urinary excretion of the waste product accounted for roughly half of the administered drug for both formulations.10PubMed Central. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control These drugs do not lower glutamine directly but reduce the upstream ammonia that drives problematic glutamine accumulation in the brain.
Dietary and Metabolic Strategies
Given that drugs targeting glutamine metabolism are experimental and available only in clinical trials, some researchers have explored dietary approaches. The most studied combination in animal models is a calorie-restricted ketogenic diet paired with a glutamine-blocking drug. In mouse models of glioblastoma, a calorie-restricted ketogenic diet enhanced the delivery of DON to tumor tissue by roughly two- to three-fold compared with a standard unrestricted diet.11PubMed Central. Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma The ketogenic diet on its own did not eliminate glutamine from the body, but the metabolic shift it creates, with lower blood glucose and higher ketone bodies, appeared to make tumors more vulnerable to glutamine-targeting drugs.
Simply restricting protein or specific high-glutamine foods has not been shown to meaningfully lower blood glutamine in humans. As mentioned earlier, the body compensates by ramping up its own production. For someone without cancer or liver disease, there is no established dietary protocol that reliably reduces systemic glutamine levels in a beneficial way. The research that does exist on diet and glutamine is almost entirely focused on creating metabolic conditions that make pharmacological glutamine blocking more effective, not on diet as a standalone solution.
How Cancer Cells Resist Glutamine Deprivation
One of the most frustrating findings in this field is how readily cancer cells adapt when you cut off their glutamine supply. This resistance is a major reason why glutaminase inhibitors alone have often fallen short in clinical trials.
When researchers blocked glutaminase in cancer cells, the cells activated a backup system: an enzyme called pyruvate carboxylase, which allowed them to use glucose-derived pyruvate instead of glutamine to feed their energy cycle.12PubMed Central. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells In other words, some tumors can simply switch fuel sources when glutamine becomes scarce.
An even more creative escape route involves macropinocytosis, a process where cells essentially gulp large chunks of protein from their surroundings, digest them internally, and extract the amino acids they need, including glutamine. Cells driven by the Ras oncogene are particularly good at this trick. Studies showed that Ras-transformed cells could maintain their glutamine supply by scavenging extracellular protein, effectively bypassing the need for free glutamine in the surrounding fluid.13PubMed Central. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells Further research found that when amino acids drop in the area around a tumor, the rate of macropinocytosis actually increases, and glutamine scarcity is the specific trigger that ramps this process up.14PubMed Central. EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis
These escape routes explain why the field has moved toward combination strategies. Blocking glutaminase alone leaves too many doors open. Combining a glutamine-targeting drug with something that also restricts glucose or blocks macropinocytosis may be necessary to corner cancer cells effectively.
The Risks of Lowering Glutamine Too Much
Glutamine is not just cancer fuel. It is the primary energy source for the cells lining your intestines, a critical building block for immune cells, and a key player in maintaining the barrier between your gut contents and your bloodstream. Reducing glutamine levels aggressively carries real physiological costs.
When intestinal cells are deprived of glutamine, the gut lining deteriorates. Research shows that glutamine depletion leads to shrinkage of intestinal villi, reduced expression of the proteins that keep gut cells sealed together, and increased intestinal permeability, sometimes called “leaky gut.”15PubMed. Glutamine and the regulation of intestinal permeability: from bench to bedside Lab studies confirm that when gut cells are starved of glutamine, their enzyme activity drops and bacteria can cross the intestinal wall more easily.16PubMed. Role of glutamine in bacterial transcytosis and epithelial cell injury This is one reason why DON, the broad glutamine antagonist, caused so much gastrointestinal damage in early trials and why newer prodrug versions are specifically designed to avoid activating in the gut.
The immune system is equally vulnerable. Both lymphocytes and macrophages burn through glutamine at high rates. They need it not only as a fuel source but as a raw material for building the DNA and RNA required when immune cells rapidly multiply in response to infection. Lymphocyte proliferation is highly dependent on the glutamine concentration available to the cells.17The Journal of Nutrition. Nonnutritive Effects of Glutamine – Section: Glutamine: influence on immune cells Dropping glutamine levels systemically could leave a person more susceptible to infections, which is an especially dangerous prospect for cancer patients already dealing with immune suppression from chemotherapy.
Exercise, Stress, and Glutamine Depletion
Prolonged, exhaustive exercise is one of the few natural situations that reliably lowers blood glutamine. Marathon running, ultraendurance events, and extended high-intensity training sessions can drop plasma glutamine levels enough to potentially compromise immune function.18Canadian Journal of Physiology and Pharmacology. Glutamine and the effects of exhaustive exercise upon the immune response This is thought to be one factor behind the “open window” period after strenuous exercise, when athletes become more susceptible to upper respiratory infections.
For most people, this is a reason to be cautious about deliberately reducing glutamine, not a useful tool for doing so. If you are exercising hard enough to significantly lower your glutamine levels, you are also likely stressing your immune system and increasing your recovery demands. Athletes actually supplement glutamine for exactly this reason. The exercise-induced drop in glutamine is a side effect of extreme exertion, not a therapeutic lever.
Other forms of physiological stress, like severe burns, major surgery, or critical illness, also deplete glutamine. In intensive care settings, clinicians have historically given glutamine supplements to critically ill patients to counteract this depletion, though the evidence on whether supplementation improves outcomes has been inconsistent. The point is that in virtually every medical context outside of cancer and liver disease, the clinical instinct runs in the opposite direction: preserve or restore glutamine rather than deplete it.
How Glutamine Enters Cells
Understanding how glutamine gets inside cells matters because blocking its transport is another avenue researchers are exploring. A transporter protein called ASCT2 (also known as SLC1A5) is the primary gateway for glutamine into cancer cells. It works by swapping glutamine for another small amino acid inside the cell, using sodium to power the exchange.19eLife. Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation Among its family of transporters, ASCT2 is the only one capable of moving glutamine, making it an appealing drug target.
Earlier theories suggested that ASCT2 worked in a tightly coupled partnership with another transporter called LAT1, but research showed that this pairing is not obligatory and does not hold across all cancer types.20PubMed Central. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5) This finding matters because it means drugs targeting ASCT2 may not need to also block LAT1 to be effective. However, blocking transport at the cell surface runs into the same problem as blocking glutaminase: if you shut the front door, cancer cells can find side entrances, including macropinocytosis.
The Combination Approach in Preclinical Research
Because single-target strategies keep running into resistance mechanisms, much of the current preclinical research focuses on hitting glutamine metabolism from multiple angles at once. The calorie-restricted ketogenic diet combined with DON in glioblastoma mouse models is one example. In those experiments, the dietary shift not only enhanced drug delivery to the tumor but also created additional metabolic stress on cancer cells by restricting glucose, their alternative energy source.11PubMed Central. Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma
Combining glutamine deprivation with radiation therapy is another approach being studied. Telaglenastat improved treatment response when combined with radiation in head and neck cancer models.6PubMed Central. Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models The logic is that cancer cells under radiation stress need glutamine to repair damage and manage oxidative stress, so cutting off their supply at the same time makes the radiation more lethal to them. That said, results vary by tumor type. In some neuroblastoma cells with amplified MYCN, combining radiation with glutamine deprivation did not significantly change the levels of oxidative stress markers, suggesting that certain genetic backgrounds may blunt this strategy’s effectiveness.21PubMed Central. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation
The honest assessment is that glutamine-targeting therapies remain a work in progress. The biology is clear: many cancers need glutamine badly, and the brain can suffer when glutamine accumulates in liver disease. But the body’s ability to compensate for glutamine depletion, cancer cells’ talent for finding alternative fuel sources, and the genuine risks of starving healthy tissues mean that no simple, safe method exists for broadly lowering glutamine. Every approach in use or development is either experimental, disease-specific, or carries significant trade-offs that require close medical supervision.